Posted by Michael Wonder on 20 Jun 2025
Cycle Pharmaceuticals’ Harliku (nitisinone) tablets receive first FDA approval as treatment for alkaptonuria
19 June 2025 - Cycle Pharmaceuticals announced that the FDA has approved Harliku (nitisinone) tablets for the reduction of urine homogentisic acid in adult patients with alkaptonuria.
The approval of Harliku is based on data from a randomised, no-treatment controlled study of 40 patients with alkaptonuria.
